OnKure Therapeutics (OKUR) Price & Analysis

Compare

403 Followers

OKUR Stock Chart & Stats

$2.86

-$0.05(-0.63%)

At close: Jan 08 4:00 PM EST

$2.86

-$0.05(-0.63%)

Day’s Range― - ―

52-Week Range$1.70 - $15.89

Previous CloseN/A

Volume8.61K

Average Volume (3M)86.56K

Market Cap

$41.94M

Enterprise Value-$50.26M

Total Cash (Recent Filing)$70.33M

Total Debt (Recent Filing)$687.00K

Price to Earnings (P/E)―

Beta0.65

Next Earnings

Mar 16, 2026

EPS Estimate

-1.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.09

Shares Outstanding12,843,434

10 Day Avg. Volume131,167

30 Day Avg. Volume86,556

Financial Highlights & Ratios

PEG Ratio-0.04

Price to Book (P/B)1.10

Price to Sales (P/S)0.00

P/FCF Ratio-2.24

Enterprise Value/Market Cap-1.20

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit119.96

Enterprise Value/Ebitda0.65

Forecast

1Y Price Target

$25.50

Price Target Upside791.61% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Analyst RecommendationAnalyst's recommendation for OnKure Therapeutics, Inc. stock is a Buy.

Clinical TrialsOKI-219 was well-tolerated across all dose levels with no serious treatment-related adverse events reported, indicating a benign safety profile.

Market OpportunitiesThe company's expansion into PI3KCA-driven vascular malformations aligns with strategies used by other major players, potentially enhancing its market position.

Bears Say

Clinical EfficacyNo objective responses have been seen to date for patients treated with OKI-219 at the 900mg dose level.

Competitive PressureThe competitive landscape is intensifying, with Eli Lilly & Co. and others presenting promising results for their PI3Ka inhibitors.

Investor SentimentData readouts have been delayed, which could impact investor sentiment in the short term.

OnKure Therapeutics News

OnKure Therapeutics files $200M mixed securities shelf

17:09 EST OnKure Therapeutics (OKUR) files $200M mixed securities shelf Published first on TheFly – the ultimate source...

23d ago

OKUR

OnKure Therapeutics reports Q3 EPS ($1.09), consensus ($1.20)

“We have made steady progress advancing our lead clinical development program, OKI-219, and are committed to leading the...

23d ago

OKUR

OnKure Therapeutics Advances Clinical Programs and Expands Focus

Onkure Therapeutics, Inc. ( ($OKUR) ) has released its Q3 earnings. Here is a breakdown of the information...

19d ago

OKUR

Promising Prospects for OnKure Therapeutics: Buy Rating Backed by OKI-219 Developments and Strategic Expansion

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on OnKure Therapeutics. The associated price target...

19d ago

OKUR

Strategic Delay and Diversification: OnKure Therapeutics Positioned for Growth with Buy Rating

Soumit Roy, an analyst from JonesTrading, reiterated the Buy rating on OnKure Therapeutics. The associated price target was...

22d ago

OKUR

OnKure Therapeutics: Strategic Advancements and Promising Clinical Developments Drive Buy Rating

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on OnKure Therapeutics today and set a price target...

22d ago

OKUR

OnKure Therapeutics Announces Sales Agreement with Leerink

An announcement from OnKure Therapeutics ( ($OKUR) ) is now available. On November 6, 2025, OnKure Therapeutics, Inc....

23d ago

OKUR

Promising Developments in OnKure Therapeutics’ PI3Kα Mutant Breast Cancer Treatment: Analyst Recommends Buy Rating

Analyst Soumit Roy of JonesTrading maintained a Buy rating on OnKure Therapeutics, with a price target of $32.00....

1M ago

OKUR

VTI ETF News, 10/9/2025

How is VTI stock faring? The Vanguard Total Stock Market ETF is up 1.59% over the past five days...

2M ago

LVO

VTI

VTI ETF News, 10/8/2025

How is VTI stock faring? The Vanguard Total Stock Market ETF is up 0.69% over the past five days...

2M ago

LVO

VTI

VTI ETF News, 10/7/2025

How is VTI stock faring? The Vanguard Total Stock Market ETF ($VTI) is up 1.15% over the past five...

2M ago

VTI

BCAB

Buy Recommendation for OnKure Therapeutics Based on Strategic Development of PI3Kα Programs and Promising OKI-219 Trial Results

Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on OnKure Therapeutics, retaining the price target of...

3M ago

OKUR

OnKure Therapeutics reports Q2 EPS ($1.14), consensus ($1.25)

“We are encouraged by the continued progress in the development of our lead asset, OKI-219, as we have...

4M ago

OKUR

One new option listing and nine option delistings on May 19th

New option listings for May 19th include Jacobs Engineering (J). Option delistings effective May 19th include BrainStorm (BCLI),...

6M ago

DFS

OKUR FAQ

What was OnKure Therapeutics’s price range in the past 12 months?

OnKure Therapeutics lowest stock price was $1.70 and its highest was $15.88 in the past 12 months.

What is OnKure Therapeutics’s market cap?

OnKure Therapeutics’s market cap is $41.94M.

When is OnKure Therapeutics’s upcoming earnings report date?

OnKure Therapeutics’s upcoming earnings report date is Mar 16, 2026 which is in 107 days.

How were OnKure Therapeutics’s earnings last quarter?

OnKure Therapeutics released its earnings results on Nov 06, 2025. The company reported -$1.09 earnings per share for the quarter, beating the consensus estimate of -$1.198 by $0.108.

Is OnKure Therapeutics overvalued?

According to Wall Street analysts OnKure Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does OnKure Therapeutics pay dividends?

OnKure Therapeutics does not currently pay dividends.

What is OnKure Therapeutics’s EPS estimate?

OnKure Therapeutics’s EPS estimate is -1.14.

How many shares outstanding does OnKure Therapeutics have?

OnKure Therapeutics has 12,843,434 shares outstanding.

What happened to OnKure Therapeutics’s price movement after its last earnings report?

OnKure Therapeutics reported an EPS of -$1.09 in its last earnings report, beating expectations of -$1.198. Following the earnings report the stock price went down -6.962%.

Which hedge fund is a major shareholder of OnKure Therapeutics?

Currently, no hedge funds are holding shares in OKUR

OnKure Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-115.64%

Trailing 12-Months

Asset Growth

9.34%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

OnKure Therapeutics

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

OnKure Therapeutics (OKUR) Earnings & Revenues

Historic Earnings Reports

OKUR Stock 12 Month Forecast

Average Price Target

$25.50

▲(791.61% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","18":"$18","35":"$35","9.5":"$9.5","26.5":"$26.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$34.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,9.5,18,26.5,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.39,5.7446153846153845,8.09923076923077,10.453846153846154,12.80846153846154,15.163076923076925,17.517692307692307,19.872307692307693,22.22692307692308,24.581538461538464,26.93615384615385,29.290769230769232,31.645384615384618,{"y":34,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.39,5.090769230769231,6.791538461538462,8.492307692307692,10.193076923076923,11.893846153846155,13.594615384615386,15.295384615384616,16.996153846153845,18.696923076923078,20.39769230769231,22.09846153846154,23.79923076923077,{"y":25.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.39,4.436923076923077,5.483846153846153,6.530769230769231,7.577692307692308,8.624615384615385,9.67153846153846,10.718461538461538,11.765384615384615,12.812307692307693,13.85923076923077,14.906153846153845,15.953076923076923,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.29,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.95,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":8.6,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.65,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.77,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.67,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.39,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >